|
| Monday, 27 April 2015, 17:54 HKT/SGT | |
| |  | |
Source: Eisai | |
|
|
|
TOKYO, Apr 27, 2015 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, Representative Corporate Officer and CEO: Haruo Naito, "Eisai") and Nihon Medi-Physics Co., Ltd. (Headquarters: Tokyo, Representative Director, President: Dr. Yutaka Takeuchi, "Nihon Medi-Physics") announced today that they have entered into a collaboration agreement to contribute to the diagnosis and treatment of dementia with Lewy bodies (DLB) in Japan.
DLB is considered to be one of Japan's three major types of dementia, alongside Alzheimer's disease and vascular dementia. According to a number of reports, DLB affects between 4.3%(1) (based on epidemiology) and 41.4%(2) (based on autopsies) of elderly patients with dementia in Japan, with the number of patients increasing due to the aging of the population. It is pointed out that DLB is difficult to be diagnosed because the disease presents characteristic symptoms such as cognitive fluctuations, visual hallucinations and parkinsonism in addition to progressive cognitive impairment.
Nihon Medi-Physics markets the brain disorder diagnostic agent DaTSCAN Injectable (ioflupane [123I], "DaTSCAN"), which is the only product indicated for the use of dopamine transporter scintigraphy in diagnosing DLB in Japan. DaTSCAN is a radiopharmaceutical for use in Single Photon Emission Computed Tomography (SPECT) imaging. Low dopamine transporter uptake in basal ganglia, one of the suggestive features included in the criteria for clinical diagnosis of DLB (determined at the 3rd international workshop on DLB), can be verified by an examination using DaTSCAN and contributes to improving the accuracy of DLB diagnosis and influencing decisions on treatment strategy.
On the other hand, Eisai markets Aricept (donepezil hydrochloride), the world's only treatment approved for the suppression of progression of dementia symptoms in DLB in Japan. Eisai has a wealth of experience and knowledge gained from more than 30 years of drug discovery in the field of dementia and information provision activities for Aricept.
Based on this agreement, both companies will share with each other information on the dementia including DLB, and work to generate new evidence as well as hold study meetings in order to improve the diagnosis and treatment of DLB.
Through this collaboration, Eisai and Nihon Medi-Physics will contribute to the diagnosis and treatment of DLB in order to further contribute to addressing the diverse needs of, and providing increased benefits to patients with DLB, and their families.
About Dementia with Lewy Bodies (DLB)
DLB is a degenerative form of dementia discovered in Japan that is pathologically characterized by decreased neurons in the brain and brainstem and the appearance of vast numbers of Lewy bodies. In neurochemistry, DLB is characterized by a loss of acetylcholine-producing neurons in the brain similar to that seen in patients with Alzheimer's disease. In addition to obligatory symptoms associated with progressive cognitive impairment, the disease also presents with behavioral and neuropsychiatric symptoms, motor disturbances, and dysautonomia. Of these, cognitive fluctuations, visual hallucinations and idiopathic parkinsonism have a high rate of incidence and are considered to be core symptoms of the disease(3). In Japan, DLB constitutes one of the three major types of dementia diagnosed, alongside Alzheimer's disease and vascular dementia, affecting between 4.3% (based on epidemiology) to 41.4% (based on autopsy) of elderly patients with dementia, according to various studies(1),(2).
About DaTscan Injection
DaTSCAN. Injectable (ioflupane [123I] injection) "DaTSCAN") is a brain imaging agent to be used in evaluating the distribution of presynaptic dopamine transporters in the striatal region of the brain for diagnosing Parkinson's Syndrome and dementia with Lewy bodies. DaTSCAN is a radiopharmaceutical used in Single Photon Emission Computed Tomography (SPECT) procedure and contains ioflupane (123I) as its active ingredient. Usually, one vial (111-185 MBq) of DaTSCAN is intravenously administered to an adult patient for brain scintigram which is taken 3 to 6 hours after administration. Dopaminergic information obtained by DaTSCAN, used as an adjunct to other diagnostic evaluations, is expected to contribute to improving accurate diagnosis and influencing decisions on treatment strategy for patients with the above diseases.
DaTSCAN, which has been approved as a pharmaceutical in 34 countries and areas globally by GE Healthcare, is considered as a standard healthcare procedure in Europe and the United States. In Japan, Nihon Medi-Physics obtained the approval of DaTSCAN in September 2013, and following the listing in the National Health Insurance Drug List in November 2013, launched the agent in January 2014.
About Nihon Medi-Physics Co., Ltd.
Nihon Medi-Physics Co., Ltd. (NMP) is a joint venture of Sumitomo Chemical Company, Limited and GE Healthcare (United Kingdom) and a leading manufacturer of radiopharmaceuticals. NMP has been working on development, manufacture and supply of high-quality radiopharmaceuticals used in diagnostic nuclear medicine valuable for disease diagnosis, and is determined to continue contribution to further improvement of medical care in Japan.
(1) MHLW Grants System - Prevalence of dementia in urban areas and measurements for living impairment in dementia: The Report for Scientific Research, 2013
(2) Wakisaka Y, Furuta A, Tanizaki Y, Kiyohara Y, Iida M, Iwaki T. Age-associated prevalence and risk factors of Lewy body pathology in a general population: the Hisayama study. Acta Neuropathol 2003; 106:374-382
(3) McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium. Neurology 2005; 65:1863-72.
For more information about NMP, please visit: http://www.nmp.co.jp/eng/index.html.
Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120
Topic: Press release summary
Source: Eisai
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
| Eisai |
| Apr 18, 2024 09:53 HKT/SGT |
|
Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category) |
| Apr 17, 2024 15:17 HKT/SGT |
|
Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan |
| Apr 3, 2024 15:24 HKT/SGT |
|
French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac And Parkinane LP to CNX Therapeutics |
| Apr 1, 2024 08:39 HKT/SGT |
|
Eisai Completes Submission of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA |
| Mar 29, 2024 14:51 HKT/SGT |
|
Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical |
| Mar 29, 2024 14:19 HKT/SGT |
|
Eisai's Brain Health Self-Check Tool "NouKNOW" is Certified as "ME-BYO BRAND" by Kanagawa Prefecture |
| Mar 29, 2024 13:32 HKT/SGT |
|
Eisai: Discovery Research on Dual Orexin Receptor Antagonist Lemborexant Honored with PSJ Award for Drug Research and Development 2024 |
| Mar 21, 2024 16:36 HKT/SGT |
|
Lifenet and Eisai Co-Develop Dementia Insurance "be" |
| Mar 21, 2024 15:10 HKT/SGT |
|
Eisai Selected as a Nadeshiko Brand 2024 as a Listed Company Excelling in Promotion of Women in the Workplace |
| Mar 6, 2024 16:47 HKT/SGT |
|
Eisai Invests in C2N to Support Simplifying the Diagnosis of Early Alzheimer's Disease to Better Serve Patients |
| More news >> |
 |
|
|
|
